Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

RMED - Catheter Precision Inc.


Previous close
0.594
0   0%

Share volume: 77,545
Last Updated: Thu 17 Aug 2023 06:00:00 AM CEST
Surgical and Medical Instrument Manufacturing : -0.56%

PREVIOUS CLOSE
CHG
CHG%

$0.59
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Fundamental analysis
19%
Profitability 0%
Dept financing 16%
Liquidity 70%
Performance 25%
Company vs Stock growth
vs
Performance
5 Days
-11.20%
1 Month
-17.51%
3 Months
-47.43%
6 Months
-79.30%
1 Year
-92.84%
2 Year
-99.52%
Key data
Stock price
$0.59
P/E Ratio 
0.00
DAY RANGE
$0.52 - $0.59
EPS 
$0.00
52 WEEK RANGE
$0.52 - $11.14
52 WEEK CHANGE
-$0.93
MARKET CAP 
3.188 M
YIELD 
N/A
SHARES OUTSTANDING 
5.368 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$109,571
AVERAGE 30 VOLUME 
$166,851
Company detail
CEO:
Region: US
Website: https://www.ramed.com/
Employees: 0
IPO year: -
Issue type: Common Stock
Market: NYSE American
Industry: Surgical and Medical Instrument Manufacturing
Sector: Manufacturing

advanced excimer laser-based vascular and dermatological therapies we are a commercial-stage medical device company leveraging our advanced excimer laser-based platform for use in the treatment of vascular and dermatological diseases. we believe our products enhance patients’ quality of life by restoring blood-flow in arteries and clearing chronic skin conditions. we currently manufacture and market two lines of products: dabra catheter and laser is cleared by the u.s. fda as a tool for the minimally invasive endovascular treatment of vascular blockages resulting from lower extremity vascular disease, which includes peripheral artery disease (pad), which commonly occurs in the legs. pharos excimer laser pharos is designed for use in the treatment of inflammatory skin conditions and is fda cleared as a tool used in the treatment of psoriasis, atopic dermatitis, and leukoderma. our goal is to become the leading medical device company marketing excimer lasers as tools for the treatment of

Recent news